Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Abiraterone and increased survival in metastatic prostate cancer

de Bono, Johann S., Logothetis, Christopher J., Molina, Arturo, Fizazi, Karim, North, Scott, Chu, Luis, Chi, Kim N., Jones, Robert J., Goodman, Oscar B., Saad, Fred, Staffurth, John Nicholas ORCID: https://orcid.org/0000-0002-7834-3172, Mainwaring, Paul, Harland, Stephen, Flaig, Thomas W., Hutson, Thomas E., Cheng, Tina, Patterson, Helen, Hainsworth, John D., Ryan, Charles J., Sternberg, Cora N., Ellard, Susan L., Fléchon, Aude, Saleh, Mansoor, Scholz, Mark, Efstathiou, Eleni, Zivi, Andrea, Bianchini, Diletta, Loriot, Yohann, Chieffo, Nicole, Kheoh, Thian, Haqq, Christopher M. and Scher, Howard I. 2011. Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine 364 (21) , pp. 1995-2005. 10.1056/NEJMoa1014618

Full text not available from this repository.

Abstract

BACKGROUND Biosynthesis of extragonadal androgen may contribute to the progression of castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy. METHODS We randomly assigned, in a 2:1 ratio, 1195 patients who had previously received docetaxel to receive 5 mg of prednisone twice daily with either 1000 mg of abiraterone acetate (797 patients) or placebo (398 patients). The primary end point was overall survival. The secondary end points included time to prostate-specific antigen (PSA) progression (elevation in the PSA level according to prespecified criteria), progression-free survival according to radiologic findings based on prespecified criteria, and the PSA response rate. RESULTS After a median follow-up of 12.8 months, overall survival was longer in the abiraterone acetate–prednisone group than in the placebo–prednisone group (14.8 months vs. 10.9 months; hazard ratio, 0.65; 95% confidence interval, 0.54 to 0.77; P<0.001). Data were unblinded at the interim analysis, since these results exceeded the preplanned criteria for study termination. All secondary end points, including time to PSA progression (10.2 vs. 6.6 months; P<0.001), progression-free survival (5.6 months vs. 3.6 months; P<0.001), and PSA response rate (29% vs. 6%, P<0.001), favored the treatment group. Mineralocorticoid-related adverse events, including fluid retention, hypertension, and hypokalemia, were more frequently reported in the abiraterone acetate–prednisone group than in the placebo–prednisone group. CONCLUSIONS The inhibition of androgen biosynthesis by abiraterone acetate prolonged overall survival among patients with metastatic castration-resistant prostate cancer who previously received chemotherapy. (Funded by Cougar Biotechnology; COU-AA-301 ClinicalTrials.gov number, NCT00638690.)

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
R Medicine > RM Therapeutics. Pharmacology
Publisher: Massachusetts Medical Society
ISSN: 0028-4793
Last Modified: 19 Oct 2022 10:40
URI: https://orca.cardiff.ac.uk/id/eprint/25171

Citation Data

Cited 3440 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item